Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces P

Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762

Intratumoral PH-762 has encouraging safety profile in the initial cohortEscalation to proceed to next dose concentrationMarlborough, Massachusetts--(Newsfile Corp. - May 28, 2024) - Phio Pharmaceuticals

Related Keywords

Michael Adams , Nasdaq , Massachusetts Newsfile Corp , Safety Monitoring Committee , Phio Pharmaceuticals Corp , Mary Spellman , Chief Medical , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Phio Pharmaceuticals , Ihr Portfolio ,